Esperion Therapeutis.Inc. buy Cantor Fitzgerald
Start price
17.12.24
/
50%
€2.41
Target price
17.12.25
€7.61
Performance (%)
25.63%
End price
18.12.25
€3.02
Summary
This prediction ended on 18.12.25 with a price of €3.02. The BUY prediction by Cantor_Fitzgerald finished with a performance of 25.63%. Cantor_Fitzgerald has a follow-up prediction for Esperion Therapeutis.Inc. where he still thinks Esperion Therapeutis.Inc. is a Buy. Cantor_Fitzgerald has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Esperion Therapeutis.Inc. | -1.904% | -1.904% | 52.394% |
| iShares Core DAX® | 2.032% | 3.499% | 24.306% |
| iShares Nasdaq 100 | -0.145% | -1.849% | 5.004% |
| iShares Nikkei 225® | 4.507% | 1.976% | 16.735% |
| iShares S&P 500 | 0.331% | -0.103% | 3.168% |
Comments by Cantor_Fitzgerald for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Esperion Therapeutics, Inc. (NASDAQ: ESPR) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $8.00 price target on the stock.
Ratings data for ESPR provided by MarketBeat
In the thread Trading Esperion Therapeutis.Inc.
Die von Cantor_Fitzgerald gewählte maximale Laufzeit wurde überschritten